NanoVibronix has launched ENvue Drive, a next-generation robotic platform being developed for automating electromagnetic navigation for bedside enteral and vascular access procedures.
The company announced the latest robotic development initiative within its ENvue Medical division.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This system is tailored to integrate with NanoVibronix’s electromagnetic guidance technology, which has been cleared by the US Good and Drug Administration (FDA) for enteral access.
The robotic platform aims to minimise the requirement of several clinicians during procedures, which is especially beneficial amidst nurse shortages.
ENvue Drive’s hands-free functionality is expected to increase consistency, safety as well as reproducibility.
NanoVibronix has outlined several development goals for ENvue Drive, including real-time, stabilised positioning at the time of nasoenteric and PICC procedures.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe platform is also designed to integrate with current ENvue consoles and software.
ENvue Drive is currently in the preclinical development phase, with engineering prototypes being created and clinical adviser input being sought.
The system has not yet been submitted for FDA clearance, but NanoVibronix plans to commence regulatory planning and submission milestones later in this year, with a functional prototype expected by the end of the year.
NanoVibronix and ENvue Medical CEO Dr Doron Besser said: “By embedding intelligent robotics into high frequency clinical workflows, starting with feeding tubes and expanding into vascular areas, we believe that we are addressing a major clinical challenge of doing more with fewer hands without compromising precision or safety while giving clinicians a new level of confidence and consistency in care.”
This development comes after NanoVibronix and ENvue Medical’s second quarter, which saw the implementation of a dual-system acquisition agreement with a Northeastern US hospital and a new US patent issuance for electromagnetic guidance system for paediatric feeding applications.
Additionally, it saw the expanded geographic reach across the Southeast, Midwest, and Northeastern US.
Headquartered in Texas, US, with research and development (R&D) in Israel, NanoVibronix focuses on acoustic-based therapeutic technologies and the ENvue Navigation Platform.
Earlier this year, the company completed the first phase of a randomised control trial with UroShield, a disposable ultrasound device designed to prevent catheter-associated urinary tract infections.
